top of page
![](https://static.wixstatic.com/media/f1a3c6_265ec25cf9e54bdda75e82e820b735e4.jpg/v1/fill/w_1920,h_1498,al_c,q_90,usm_0.66_1.00_0.01,enc_avif,quality_auto/f1a3c6_265ec25cf9e54bdda75e82e820b735e4.jpg)
![](https://static.wixstatic.com/media/f1a3c6_7f4b4095586a4793bda38d9a23959441.jpg/v1/fill/w_670,h_338,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/f1a3c6_7f4b4095586a4793bda38d9a23959441.jpg)
Recent Research
![](https://static.wixstatic.com/media/f1a3c6_dbcfb535666149fda4be7049a66de6c3.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/f1a3c6_dbcfb535666149fda4be7049a66de6c3.webp)
![PFE: ACIP: Prevnar protects against some new but not all old infections](https://static.wixstatic.com/media/f1a3c6_dbcfb535666149fda4be7049a66de6c3.jpg/v1/fill/w_319,h_218,fp_0.50_0.50,q_90,enc_auto/f1a3c6_dbcfb535666149fda4be7049a66de6c3.webp)
Feb 23, 2023
PFE: ACIP: Prevnar protects against some new but not all old infections
New data from Pfizer’s pneumococcal vaccine reveals inferiority to an important serotype 3 that makes up approximately one third of cases
![](https://static.wixstatic.com/media/f1a3c6_d018a78cb2bf4ace86a6e07570660a81~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/f1a3c6_d018a78cb2bf4ace86a6e07570660a81~mv2.webp)
![PFE pipeline Swim in a big pond if you're 2nd to jump in](https://static.wixstatic.com/media/f1a3c6_d018a78cb2bf4ace86a6e07570660a81~mv2.jpg/v1/fill/w_319,h_319,fp_0.50_0.50,q_90,enc_auto/f1a3c6_d018a78cb2bf4ace86a6e07570660a81~mv2.webp)
Dec 21, 2022
PFE pipeline Swim in a big pond if you're 2nd to jump in
We examine in detail, the prospects of five near term Pfizer pipeline assets, slated for the FDA over the next 3 years and find that there a
![](https://static.wixstatic.com/media/f1a3c6_7f4b4095586a4793bda38d9a23959441.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/f1a3c6_7f4b4095586a4793bda38d9a23959441.webp)
![NOVN Kisqali incumbent competitor Ibrance shows no OS benefit](https://static.wixstatic.com/media/f1a3c6_7f4b4095586a4793bda38d9a23959441.jpg/v1/fill/w_319,h_180,fp_0.50_0.50,q_90,enc_auto/f1a3c6_7f4b4095586a4793bda38d9a23959441.webp)
Jun 21, 2022
NOVN Kisqali incumbent competitor Ibrance shows no OS benefit
ASCO2022 saw the eventual presentation of Pfizer's PALOMA-2 study, where, as we highlighted in our February 2020 Foveal report NOVN...
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page